Breakthroughs in Medical Isotope Technology 2019 Mo-99 Topical - - PowerPoint PPT Presentation

Breakthroughs in Medical Isotope Technology

2019 Mo-99 Topical Meeting

Heather Murphy, Commercial Operations Manager BWXT ITG Canada, Inc.

BWXT Company Overview

1) As of June 30, 2019

2

Nordion Medical Isotopes Business Acquisition

• Reputation as a pioneer in reactor and cyclotron

isotope and radiopharmaceutical production

• Extensive infrastructure – cyclotrons, hotcells,

manufacturing suites, labs

• 40 year relationship with TRIUMF (Vancouver)
• Highly trained, experienced, professional staff
• CNSC-licensed facilities in Kanata, Ontario and

Vancouver, BC

• World class nuclear transport container fleet
• Acquisition Closed: July 30, 2018
• Current Products Include:
• Iodine-123/Oral Iodine-123
• Strontium-82
• Indium-111
• Palladium-103
• In-111 oxyquinoline (Q3, 2019)
• Contract Manufacturing

Tc-99m – A Powerful Diagnostic Tool

Why Tc-99m is so critical?

• Physiological diagnostic technique
• Used in 80% of all nuclear medicine imaging

scans, 30-40M patients per year globally

• Applications in cardiology, GI, oncology,

neurology, pulmonary

• Considered the gold standard diagnostic test

for many conditions

Over 5,000 lives will be directly impacted by Tc-99m in the next 90 min

How is it made (historically)?

• Supplied in a Tc-99m generator
• Decay product of Mo-99
• Mo-99 produced from the fission of U-

235 targets

• Targets irradiated primarily in research

and test reactors outside of North America

Mo-99/Tc-99m Market Issues

• Security of Supply
• Desire for long term, reliable and locally

manufactured supply

• Reduction in use of uranium in targets
• Proliferation risk, inefficient, highly active liquid

waste

• Sustainable economics along supply chain
• Nuclear Energy Agency’s High-level Group on

Security of Supply of Medical Radioisotopes (HLG-MR) full cost recovery principle

• Healthcare System Cost Containment
• Diagnostic reimbursement pressure

Tc-99m Generator Development

• Designed to be user friendly
• Comparable to currently available

generators

• Sizes (Activity level)
• Eluent volume and activity

concentration

• Elution time
• Dimensions/weight

Tc-99m Generator Prototype

Darlington Nuclear Irradiation Site

• A world leader in reliable operation of multiple CANDU reactors
• Proven nuclear safety track record
• Multiple reactors on one site
• Longtime producer of radioisotopes – Co-60, Tritium

Progress Update

• Target Design and Manufacturing
• Targets designed
• Manufacturing facility constructed and initial

targets manufactured for testing

• Target Delivery System
• Full scale mock-up facility constructed
• Testing underway
• Target Processing
• Processing equipment designed and configured
• Full scale pilot plant constructed
• Test runs underway
• Processing/Manufacturing Facility
• Hot cell modifications underway
• New hot cells designed and ordered
• Tc-99m Generator
• Finalizing design elements

BWXT Isotope Technologies: Solving the Key Industry Issues Local irradiation, processing and manufacturing

• Returning North America to a leadership role in

nuclear medicine

• Leveraging BWXT innovation and former Nordion

assets to de-risk commercialization

• Securing local supply for North American patients

Uranium-free targets

• Completely eliminate proliferation risk
• No long-lived isotopic fission waste

Reliable, redundant irradiation in multiple reactors

• Utilize highly reliable reactors
• Predictable, high operating schedule